Subjects with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:\r\n* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills\r\n* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel\r\n* Active peptic ulcer disease\r\n* Malabsorption syndrome
Patients with clinically significant gastrointestinal abnormalities that may affect absorption of the investigational product are NOT eligible for participation; these may include (but are not limited to):\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowel
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome \r\n* Major resection of the stomach or small bowel
Any gastrointestinal (GI) disorder that may affect absorption of oral medications in the opinion of the treating investigator, such as malabsorption syndrome or major bowel or stomach resection
Inability to swallow capsules, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of study drugs, major resection of the stomach or small bowel, or gastric bypass procedure
Patients unable to swallow oral medications, or patients with gastrointestinal conditions (e.g. malabsorption, gastric or small bowel resection, etc.) deemed to jeopardize intestinal absorption
Inability to swallow capsules, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of study drugs, major resection of the stomach or small bowel, or gastric bypass procedure
Inability or unwillingness to swallow capsules; patients with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:\r\n* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills;\r\n* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel;\r\n* Active peptic ulcer disease;\r\n* Malabsorption syndrome
Clinically significant gastrointestinal abnormality that would affect the absorption of drug such as gastrointestinal dysfunction, malabsorption syndrome, major resection of the small bowel or total gastrectomy or inflammatory bowel disease
Any condition that may impair the ability to absorb oral medications/investigational product including: prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel; active peptic ulcer disease; and malabsorption syndrome
Inability to swallow pills, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of study drugs, major resection of the stomach or small bowel, or gastric bypass procedure
Clinically significant gastrointestinal abnormalities that may affect absorption of pazopanib, including (but not limited to) malabsorption syndrome or major resection of the stomach or small bowel
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome \r\n* Major resection of the stomach or small bowel
Patients with malabsorption syndrome, disease significantly affecting gastrointestinal function, or major resection of the stomach or small bowel that could affect absorption of the study drug.
Subjects with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:\r\n* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills\r\n* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel\r\n* Active peptic ulcer disease\r\n* Malabsorption syndrome
Patients with any condition that may impair the ability to absorb oral medications/investigational product including:\r\n* Prior surgical procedures affecting absorption including, but not limited to, major resection of stomach or small bowel\r\n* Active peptic ulcer disease\r\n* Malabsorption syndrome
Patients must be capable of taking and absorbing oral medications; a patient must be clear of the following:\r\n* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow tablets\r\n* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel\r\n* Active peptic ulcer disease\r\n* Malabsorption syndrome
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product, including but not limited to:\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowel
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowel resulting in dumping syndrome or clinical signs of malabsorption
Clinically significant gastrointestinal abnormalities that may affect absorption of pazopanib, including (but not limited to) malabsorption syndrome or major resection of the stomach or small bowel
Patients unable to take oral medications or those with history of malabsorption due to bowel resection or gastrointestinal disease
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowel
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to: \r\n* Malabsorption syndrome \r\n* Major resection of the stomach or small bowel\r\n* Presence of uncontrolled infection\r\n* Corrected QT interval (QTc) > 480 msecs using Bazett’s formula
Inability to swallow capsules, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of study drugs, major resection of the stomach or small bowel, or gastric bypass procedure
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome or\r\n* Major resection of the stomach or small bowel
Patient must not have any clinically significant abnormality that may affect absorption of investigational product including, but not limited to, malabsorption syndrome or major resection of the stomach or small bowel
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome \r\n* Major resection of the stomach or small bowel and experiencing the “dumping” syndrome
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowel
Subjects with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:\r\n* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills\r\n* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel\r\n* Active peptic ulcer disease, not on a proton pump inhibitor\r\n* Malabsorption syndrome
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to: \r\n* Malabsorption syndrome \r\n* Major resection of the stomach or small bowel
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowel
Patients with significant gastrointestinal disorder that, in the opinion of the investigator, could interfere with absorption of quinacrine and/or erlotinib (eg, Crohn’s disease, small or large bowel resection, malabsorption syndrome)
Presence of any clinically significant gastrointestinal (GI) abnormality or other condition(s) that may alter absorption such as malabsorption syndrome or major resection of the stomach or substantial portion of the small intestine
Patients must be capable of taking and absorbing oral medications; a patient must be clear of the following: any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow tablets; prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel; active peptic ulcer disease; malabsorption syndrome
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to: malabsorption syndrome; major resection of the stomach or small bowel
Clinically significant gastrointestinal abnormalities that may affect absorption (e.g. malabsorption syndrome, major resection of the stomach or small bowel)
Patients must not have clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowel
